Sepragen.com

Home | Contact Us 


Online Catalog


View our online catalog.
For further information or for a quotation, call 1-510-475-0650 or email us at sales@sepragen.com.



How Can We Help You?
Click here to contact us!

 



Sepragen Successfully Completes Research Using a National Science Foundation Grant, to Advance Stem Cell Bioreactors

January 24th 2019, Hayward, CA. Sepragen Corporation announced today it had successfully completed research using a grant from the National Science Foundation to demonstrate the feasibility of using a "wicking" matrix bioreactor (WMB) for expansion of hiPSCs for tissue engineering and regenerative medicine applications.

"There aren’t any established devices or techniques for large scale growth and expansion of stem cells. This is deemed a limiting factor for commercial advancement in this promising field of regenerative medicine. Sepragen has been researching a highly innovative bioreactor for this sought after application" states Vinit Saxena, CEO of Sepragen.

The unique bioreactor from Sepragen enables precision control of gassing conditions leading to potentially high viabilities of large cell populations with minimal spontaneous and uncontrolled differentiation. This grants targets the use of the bioreactor for growing beta islets cells. Sepragen was able to demonstrate proof-of-principal for the utility of the WMB for regenerative medicine applications.

The work is being done at Sepragen’s Hayward location.

For more information Contact:
Ali Pervez
Sepragen Corporation
Tel: 510-475-0650
www.sepragen.com

Return to News Archives main page



The statements in this release that relate to future events or performance, statements about growth, future regulatory clearances, levels of sales and market size and future manufacturing capacity and efficiencies are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to the development of markets for and commercial acceptance of the company's products and services, the availability of components, competitors' product introductions and other risks identified in the company's SEC filings. Actual results may differ from those described in these forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.


Company | Products | News and Events | Contact Us | Terms and Conditions | Privacy Policy © 2018 Sepragen Corporation. All rights reserved. (510) 475-0650